APA (7th ed.) Citation

Wu, C., Hu, Y., Sanz, I., Singhal, S., Kahlenberg, J. M., Kim, J. H., & Catlett, I. M. (2023). LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: Pharmacodynamic analysis from the phase 2 PAISLEY study. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Wu, Chun, Yanhua Hu, Ignacio Sanz, Shalabh Singhal, J Michelle Kahlenberg, Jin Hyang Kim, and Ian M. Catlett. LSO-015 Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study. BMJ Publishing Group, 2023.

MLA (9th ed.) Citation

Wu, Chun, et al. LSO-015 Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study. BMJ Publishing Group, 2023.